Delivery Order SPE2DB22D3004-SPE2DB24FPU83
Award Date 3/28/24
Potential Completion Date 3/29/24
Potential Value $4.7K
Federal Agency
Ultimate Awardee
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of HUMIRA(CF) PEN 40 MG/0.4 MLS pharmaceutical products. The contract has a potential value of $2,770.74 and a completion date of February 1, 2024. Amerisourcebergen Drug Corp is the prime contractor for this delivery order, which is issued under a larger $999,999,999.00 indefinite delivery contract (IDC) the company...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, to provide HUMIRA(CF) PEN 40 MG/0.4 MLS pharmaceutical products. This $6,369.88 contract has an ultimate completion date of April 9, 2024 and was awarded on April 8, 2024. AmerisourceBergen Drug Corp holds an indefinite delivery contract (IDC) with DLA valued up to $999,999,999.00 through December 31, 2025, which serves as the...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide the HUMIRA(CF) PEN 40 MG/0.4 MLS pharmaceutical product. The $4,455.88 order has a completion date of February 28, 2024. Amerisourcebergen Drug Corp holds an indefinite delivery contract (IDC) with DLA valued up to $999,999,999.00 through December 31, 2025, which serves as the primary vehicle for the company to deliver...
- The U.S. Defense Logistics Agency (DLA) awarded a Firm Fixed Price delivery order contract valued at $13,901.54 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide HUMIRA(CF) PEN 40 MG/0.4 MLS pharmaceutical products. This order is part of a larger Indefinite Delivery Contract (IDC) valued up to $999,999,999.00 that Amerisourcebergen holds with DLA Troop Support Medical, which serves as the primary vehicle for the company to deliver a wide range of...
- The U.S. Defense Logistics Agency (DLA) awarded a delivery order contract to Amerisourcebergen Drug Corp (a subsidiary of Amerisourcebergen Corporation) for the supply of HUMIRA(CF) PEN 40 MG/0.4 MLS. The $2,770.74 firm fixed price contract has a period of performance through May 2, 2024. Amerisourcebergen holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as the primary vehicle for the company to provide a comprehensive range of...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical has awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide Humira Pen 40 mg/0.8 ml pharmaceutical products. The contract has a potential value of $4,617.90 and a completion date of March 7, 2024. Amerisourcebergen Drug Corp is the prime contractor for this delivery order, which is not associated with any set-aside program. Amerisourcebergen Drug Corp...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide HUMIRA(CF) PEN 40 MG/0.4 MLS pharmaceuticals. The contract, valued at $6,641.07, has a completion date of February 26, 2024. Amerisourcebergen Drug Corp, a for-profit organization, serves as the prime contractor and is not subject to any set-aside designations for this award. The contract is part of Amerisourcebergen...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, for the supply of Humira Pen 40 mg/0.8 ml pharmaceutical products. The $14,933.19 contract has a performance period through March 21, 2024. AmerisourceBergen Drug Corp serves as a prime contractor providing a wide range of pharmaceutical products and medical supplies to U.S. government agencies, including the Department of...
- The U.S. Defense Logistics Agency (DLA) awarded a Delivery Order contract worth $4,098.96 to AmerisourceBergen Drug Corp's Corporate Office Division on May 20, 2024. The contract is for the supply of HUMIRA(CF) PEN 40 MG/0.4 MLS, a pharmaceutical product. This Delivery Order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that AmerisourceBergen holds with DLA Troop Support Medical, which serves as the primary vehicle for the company to provide a wide...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical distribution company Amerisourcebergen Corporation, to supply the medication HUMIRA(CF) PEN 40 MG/0.4 MLS. The $3,694.32 contract has a completion date of February 8, 2024 and is not set aside for any specific business type. Amerisourcebergen Drug Corp holds a larger indefinite delivery contract (IDC) with DLA worth up to...
- SPE2DB22D3004Indefinite Delivery Contract
- SPE2DB22D3004-SPE2DB24FPU83Delivery Order
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of HUMIRA(CF) PEN 40 MG/0.4 MLS pharmaceutical products. The $4,711.22 contract has a period of performance through March 29, 2024 and was not set aside for any specific business type. Amerisourcebergen Drug Corp holds an indefinite delivery contract with DLA valued at up to $999,999,999.00 through December 31, 2025, which serves as the primary vehicle for the company to provide a wide range of pharmaceutical and medical supplies to support the Department of Defense's military treatment programs and facilities worldwide.
Generated 6/27/24, 10:35 AM
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.7k | 3/28/24 |